Longevity medicine is moving into mainstream care
Doctors today rarely focus on slowing aging itself. That is about to change. A growing number of countries are reconsidering how to structure their health systems around preventing age-related disease.
A commentary on Fight Aging! describes how longevity medicine will move from niche to mainstream over the coming years. The premise is straightforward: the majority of serious disease and death has aging as its primary driver. A medical system that only intervenes when organs fail is structurally too late.
Italy as a case study
The piece points to an Italian position paper proposing reform of the national health service. Italy has the highest share of adults over 65 in the EU. Healthy life expectancy there lags total life expectancy by more than fifteen years. Over sixty percent of adults aged 75 and older live with multiple chronic conditions simultaneously. The researchers advocate for early, risk-stratified monitoring using biomarkers and digital diagnostics, as a complement to the current hospital-centred model.
Such proposals remain exploratory. The clinical utility of most biological age biomarkers has not yet been established.
What the transition will look like in practice
The first phase will be modest, the commentary argues. It will involve lifestyle guidance, weight management, and drugs such as rapamycin, an immunosuppressant that extends lifespan in animal studies but is still being evaluated in humans. Impressive treatments targeting aging itself remain further off.
The economic driver is notable: governments are increasingly motivated by rising healthcare costs to invest in delaying age-related disease, not just treating it. The World Economic Forum and the IMF now cite population aging as one of the largest economic risks of this century.
From a longevity perspective, the direction is clear: preventive, biomarker-guided care is the logical next step. But the evidence base for specific interventions still needs to be largely built.
Search terms: healthspan preventive medicine, rapamycin lifespan extension, biomarkers biological aging